Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus document on the management of renal disease in HIV-infected patients.
AIDS Working Group (GESIDA) of the Spanish Society of InfectiousDiseases and Clinical Microbiology (SEIMC); Spanish Society of Nephrology (S.E.N.); Spanish Society of Clinical Chemistry and Molecular Pathology (SEQC); Górriz JL, Gutiérrez F, Trullas JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofan F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gracia S, Iribarren JA, Knobel H, López-Aldeguer J, Lozano F, Martínez-Castelao A, Martínez E, Mazuecos MA, Miralles C, Montañés R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaría JM, Sanz J, Sanz J, Miró JM. AIDS Working Group (GESIDA) of the Spanish Society of InfectiousDiseases and Clinical Microbiology (SEIMC), et al. Among authors: miralles c. Nefrologia. 2014;34 Suppl 2:1-81. doi: 10.3265/Nefrologia.pre2014.Jul.12674. Nefrologia. 2014. PMID: 25467377 Free article. English, Spanish.
[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
Polo R, José Galindo M, Martínez E, Alvarez J, Arévalo JM, Asensi V, Cánoves D, Cáncer E, Collazos J, Estrada V, Gómez-Candela C, Johnston S, Locutura J, López-Aldeguer J, Lozano F, Miralles C, Muñoz-Sanz A, Ortega E, Pascua J, Pedrol E, Pulido F, San Martín M, Sanz J, Viciana P, Chamorro L; Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS). Polo R, et al. Among authors: miralles c. Enferm Infecc Microbiol Clin. 2006 Feb;24(2):96-117. doi: 10.1157/13085017. Enferm Infecc Microbiol Clin. 2006. PMID: 16545318 Spanish.
Recommendations from SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA on nutrition in the HIV-infected patient.
Polo R, Gómez-Candela C, Miralles C, Locutura J, Alvarez J, Barreiro F, Bellido D, Câncer E, Cánoves D, Domingo P, Estrada V, Fumaz CR, Galindo MJ, García-Benayas T, Iglesias C, Irles JA, Jiménez-Nacher I, Lozano F, Marqués I, Martínez-Alvarez JR, Mellado MJ, Miján A, Ramos JT, Riobo P; SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA. Polo R, et al. Among authors: miralles c. Nutr Hosp. 2007 Mar-Apr;22(2):229-43. Nutr Hosp. 2007. PMID: 17416041 Review.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V; PRESCO Study Group. Núñez M, et al. Among authors: miralles c. AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82. doi: 10.1089/aid.2007.0011. AIDS Res Hum Retroviruses. 2007. PMID: 17725413 Clinical Trial.
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.
Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group. Arribas JR, et al. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5. J Acquir Immune Defic Syndr. 2009. PMID: 19349870 Clinical Trial.
The changing face of HIV/AIDS in treated patients.
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. Llibre JM, et al. Among authors: miralles c. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633. Curr HIV Res. 2009. PMID: 19601771 Review.
188 results